|
1
|
Gutiérrez-Castañeda LD, Tovar-Parra D,
Quintero G, Amezquita L, Guerrero C and Sanabria D: Isolation and
phenotypic characterization of tumor cells of patients with a
diagnosis of ovarian cancer. J Cell Physiol. 235:3320–3328. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antar A, AlJawad H, AlMuslim A and
El-Majzoub N: Isolated late recurrence of epithelial ovarian cancer
in cervical lymph nodes. Eur J Gynaecological Oncol. 40:1067–1069.
2019.
|
|
3
|
Bouberhan S, Shea M and Cannistra SA:
Advanced epithelial ovarian cancer: Do more options mean greater
benefits? J Clin Oncol. 37:1359–1364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zuberi M, Mir R, Khan I, Javid J, Guru SA,
Bhat M, Sumi MP, Ahmad I, Masroor M, Yadav P, et al: The promising
signatures of circulating microRNA-145 in epithelial ovarian cancer
patients. MicroRNA. 9:49–57. 2019. View Article : Google Scholar
|
|
5
|
Lalremmawia H and Tiwary BK:
Identification of molecular biomarkers for ovarian cancer using
computational approaches. Carcinogenesis. 40:742–748. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ida T, Fujiwara H, Kiriu T, Taniguchi Y
and Kohyama A: Relationship between the precursors of high grade
serous ovarian cancer and patient characteristics: Decreased
incidence of the p53 signature in pregnant women. J Gynecol Oncol.
30:e962019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kreuzinger C, von der Decken I, Wolf A,
Gamperl M, Koller J, Karacs J, Pfaffinger S, Bartl T, Reinthaller
A, Grimm C, et al: Patient-derived cell line models revealed
therapeutic targets and molecular mechanisms underlying disease
progression of high grade serous ovarian cancer. Cancer Lett.
459:1–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Clifford C, Vitkin N, Nersesian S,
Reid-Schachter G, Francis JA and Koti M: Multi-omics in high-grade
serous ovarian cancer: Biomarkers from genome to the immunome. Am J
Reprod Immunol. 80:e129752018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gadducci A, Guarneri V, Peccatori FA,
Ronzino G, Scandurra G, Zamagni C, Zola P and Salutari V: Current
strategies for the targeted treatment of high-grade serous
epithelial ovarian cancer and relevance of BRCA mutational status.
J Ovarian Res. 12:92019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ivy SP, Kunos CA, Arnaldez FI and Kohn EC:
Defining and targeting wild-type BRCA high-grade serous ovarian
cancer: DNA repair and cell cycle checkpoints. Expert Opin Investig
Drugs. 28:771–785. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song K, Wang Y, Li Y, Ding C, Cai R, Tao
G, Zhao P, Xia Q and He H: A convenient, rapid, sensitive, and
reliable spectrophotometric assay for adenylate kinase activity.
Molecules. 24:6632019. View Article : Google Scholar
|
|
12
|
Liu R, Ström AL, Zhai J, Gal J, Bao S,
Gong W and Zhu H: Enzymatically inactive adenylate kinase 4
interacts with mitochondrial ADP/ATP translocase. Int J Biochem
Cell Biol. 41:1371–1380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoneda T, Sato M, Maeda M and Takagi H:
Identification of a novel adenylate kinase system in the brain:
Cloning of the fourth adenylate kinase. Brain Res Mol Brain Res.
62:187–195. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Panayiotou C, Solaroli N, Johansson M and
Karlsson A: Evidence of an intact N-terminal translocation sequence
of human mitochondrial adenylate kinase 4. Int J Biochem Cell Biol.
42:62–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyoshi K, Akazawa Y, Horiguchi T and Noma
T: Localization of adenylate kinase 4 in mouse tissues. Acta
Histochem Cytochem. 42:55–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong F, Binas B, Moon JH, Kang SS and Kim
HJ: Differential expression of adenylate kinase 4 in the context of
disparate stress response strategies of HEK293 and HepG2 cells.
Arch Biochem Biophys. 533:11–17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jan YH, Tsai HY, Yang CJ, Huang MS, Yang
YF, Lai TC, Lee CH, Jeng YM, Huang CY, Su JL, et al: Adenylate
kinase-4 is a marker of poor clinical outcomes that promotes
metastasis of lung cancer by downregulating the transcription
factor ATF3. Cancer Res. 72:5119–5129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jan YH, Lai TC, Yang CJ, Huang MS and
Hsiao M: A co-expressed gene status of adenylate kinase 1/4 reveals
prognostic gene signature associated with prognosis and sensitivity
to EGFR targeted therapy in lung adenocarcinoma. Sci Rep.
9:123292019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jan YH, Lai TC, Yang CJ, Lin YF, Huang MS
and Hsiao M: Adenylate kinase 4 modulates oxidative stress and
stabilizes HIF-1α to drive lung adenocarcinoma metastasis. J
Hematol Oncol. 12:122019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xin F, Yao DW, Fan L, Liu JH and Liu XD:
Adenylate kinase 4 promotes bladder cancer cell proliferation and
invasion. Clin Exp Med. 19:525–534. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zang C, Zhao F, Hua L and Pu Y: The
miR-199a-3p regulates the radioresistance of esophageal cancer
cells via targeting the AK4 gene. Cancer Cell Int. 18:1862018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y, Zhao Z, Xie C and Zhao Y:
Dual-targeting liposome modified by glutamic hexapeptide and folic
acid for bone metastatic breast cancer. Chem Phys Lipids.
228:1048822020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Z, Zhao Y, Xie C, Chen C, Lin D, Wang
S, Lin D, Cui X, Guo Z and Zhou J: Dual-active targeting liposomes
drug delivery system for bone metastatic breast cancer: Synthesis
and biological evaluation. Chem Phys Lipids. 223:1047852019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamamoto TM, McMellen A, Watson ZL,
Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim
H, Cittelly DM, et al: Activation of Wnt signaling promotes
olaparib resistant ovarian cancer. Mol Carcinog. 58:1770–1782.
2019. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Secord AA, McCollum M, Davidson BA,
Broadwater G, Squatrito R, Havrilesky LJ, Gabel AC, Starr MD, Brady
JC, Nixon AB and Duska LR: Phase II trial of nintedanib in patients
with bevacizumab-resistant recurrent epithelial ovarian, tubal, and
peritoneal cancer. Gynecol Oncol. 153:555–561. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lichtenfels R, Dressler SP, Zobawa M,
Recktenwald CV, Ackermann A, Atkins D, Kersten M, Hesse A,
Puttkammer M, Lottspeich F and Seliger B: Systematic comparative
protein expression profiling of clear cell renal cell carcinoma: A
pilot study based on the separation of tissue specimens by
two-dimensional gel electrophoresis. Mol Cell Proteomics.
8:2827–2842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fujisawa K, Terai S, Takami T, Yamamoto N,
Yamasaki T, Matsumoto T, Yamaguchi K, Owada Y, Nishina H, Noma T
and Sakaida I: Modulation of anti-cancer drug sensitivity through
the regulation of mitochondrial activity by adenylate kinase 4. J
Exp Clin Cancer Res. 35:482016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lei W, Yan C, Ya J, Yong D, Yujun B and
Kai L: MiR-199a-3p affects the multi-chemoresistance of
osteosarcoma through targeting AK4. BMC Cancer. 18:6312018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji Y, Yang C, Tang Z, Yang Y, Tian Y, Yao
H, Zhu X, Zhang Z, Ji J and Zheng X: Adenylate kinase hCINAP
determines self-renewal of colorectal cancer stem cells by
facilitating LDHA phosphorylation. Nat Commun. 8:153082017.
View Article : Google Scholar : PubMed/NCBI
|
